Enliven Therapeutics Stock Alpha and Beta Analysis
| ELVN Stock | 25.41 1.06 4.35% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Enliven Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Enliven Therapeutics over a specified time horizon. Remember, high Enliven Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Enliven Therapeutics' market risk premium analysis include:
Beta 1.07 | Alpha (0.01) | Risk 2.77 | Sharpe Ratio 0.0993 | Expected Return 0.27 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Enliven |
Enliven Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Enliven Therapeutics market risk premium is the additional return an investor will receive from holding Enliven Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Enliven Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Enliven Therapeutics' performance over market.| α | -0.01 | β | 1.07 |
Enliven Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Enliven Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Enliven Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Enliven Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Enliven Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Enliven Therapeutics shares will generate the highest return on investment. By understating and applying Enliven Therapeutics stock market price indicators, traders can identify Enliven Therapeutics position entry and exit signals to maximize returns.
Enliven Therapeutics Return and Market Media
The median price of Enliven Therapeutics for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 25.51 with a coefficient of variation of 10.03. The daily time series for the period is distributed with a sample standard deviation of 2.57, arithmetic mean of 25.59, and mean deviation of 2.28. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 649 shares by Heyman Richard A. of Enliven Therapeutics at 27.5 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 1270 shares by Heyman Richard A. of Enliven Therapeutics at 22.408 subject to Rule 16b-3 | 09/16/2024 |
3 | Enliven Therapeutics director sells 28,458 in company stock | 09/18/2024 |
4 | Disposition of 2825 shares by Heyman Richard A. of Enliven Therapeutics at 27.5057 subject to Rule 16b-3 | 10/04/2024 |
5 | Disposition of 1270 shares by Benjamin Hohl of Enliven Therapeutics at 27.5081 subject to Rule 16b-3 | 10/07/2024 |
6 | Enliven Therapeutics CEO sells over 410k in company stock | 10/08/2024 |
7 | Disposition of 2830 shares by Kintz Samuel of Enliven Therapeutics at 28.5264 subject to Rule 16b-3 | 10/09/2024 |
8 | Disposition of 2000 shares by Benjamin Hohl of Enliven Therapeutics at 25.3338 subject to Rule 16b-3 | 10/10/2024 |
9 | Disposition of 1270 shares by Heyman Richard A. of Enliven Therapeutics at 27.6719 subject to Rule 16b-3 | 10/15/2024 |
10 | Disposition of 816 shares by Collins Helen Louise of Enliven Therapeutics at 30.003 subject to Rule 16b-3 | 10/18/2024 |
11 | Enliven Therapeutics COO Anish Patel sells 21,482 in stock | 10/22/2024 |
12 | Richard A. Heyman Sells 817 Shares of Enliven Therapeutics, Inc. Stock | 10/25/2024 |
13 | Disposition of 650 shares by Benjamin Hohl of Enliven Therapeutics at 29.111 subject to Rule 16b-3 | 10/28/2024 |
14 | Enliven Therapeutics CFO Benjamin Hohl sells shares worth 178,484 | 10/30/2024 |
15 | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 11/13/2024 |
16 | RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. | 11/15/2024 |
17 | Disposition of 526 shares by Kintz Samuel of Enliven Therapeutics at 27.5371 subject to Rule 16b-3 | 11/20/2024 |
18 | Disposition of 1547 shares by Patel Anish of Enliven Therapeutics at 25.0111 subject to Rule 16b-3 | 11/22/2024 |
About Enliven Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Enliven or other stocks. Alpha measures the amount that position in Enliven Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Enliven Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Enliven Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enliven Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Enliven Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Enliven Therapeutics. Please utilize our Beneish M Score to check the likelihood of Enliven Therapeutics' management manipulating its earnings.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Enliven Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Enliven Therapeutics Backtesting, Enliven Therapeutics Valuation, Enliven Therapeutics Correlation, Enliven Therapeutics Hype Analysis, Enliven Therapeutics Volatility, Enliven Therapeutics History and analyze Enliven Therapeutics Performance. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Enliven Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.